BRBioRestorative Therapies, Inc. BRTX · NASDAQ
$1.62 +8.00% (+$0.12)
- Market cap
- $2.07M
- Enterprise value
- -$1.01M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 5.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -464.9%
- Gross margin
- 92.1%
- Net margin
- -3,089.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.74
- Free float
- 87.5%
About the company
BioRestorative Therapies, Inc. (BRTX) is a biotechnology company focusing on the development and commercialization of therapeutic therapies in the field of regenerative medicine. The company specializes in developing therapeutic products that utilize patients' own cells and tissues to support the healing and regeneration of damaged tissues. BioRestorative Therapies targets the treatment of various health conditions, including orthopedic disorders, degenerative diseases, and more. With the growing interest in regenerative medicine and the need for new treatment approaches, BioRestorative Therapies, Inc. has the potential for sustained growth. BioRestorative Therapies, Inc. (BRTX) shares might be an interesting choice for investors seeking involvement in the biotechnology and regenerative medicine industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Katharyn Field
Employees
14
Headquarters
Melville
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number